Novo’s Promising China Obesity Drug Records Mid-Stage Trial Win
An experimental drug Novo Nordisk licensed last year has shown notable weight loss in a mid-stage study in China, boosting the company’s search for newer products that could sustain its growth in the obesity market.
📰 Original Source
Read full article at Bloomberg →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.